⌘K
Loading ticker…
As of 2026-08-24, Enveric Biosciences, Inc. Common Stock (ENVB) has a 3-month relative strength percentile of 11 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 31. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.1%, relative volume 0.40×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ENVB is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -0.4% / -52.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ENVB appears in 1 ETF as of Mar 2026: PSIL at 0.16% weight, $33K notional.
Held by 1 ETFs · $33K across latest filings · largest weight 0.16% (PSIL).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSIL | 0.16% | $33K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ENVB Jan avg: -21.48% median: -31.38% win: 25% σ: 43.09% n: 4 2022-04-12 → 2026-07-31 | ENVB Feb avg: 20.74% median: 7.36% win: 50% σ: 56.71% n: 4 2022-04-12 → 2026-07-31 | ENVB Mar avg: -29.80% median: -25.70% win: 0% σ: 14.89% n: 4 2022-04-12 → 2026-07-31 | ENVB Apr avg: 19.15% median: -5.04% win: 40% σ: 47.72% n: 5 2022-04-12 → 2026-07-31 | ENVB May avg: 6.52% median: -17.02% win: 20% σ: 69.35% n: 5 2022-04-12 → 2026-07-31 | ENVB Jun avg: -13.67% median: -19.57% win: 40% σ: 19.46% n: 5 2022-04-12 → 2026-07-31 | ENVB Jul avg: -13.93% median: -18.99% win: 40% σ: 21.37% n: 5 2022-04-12 → 2026-07-31 | ENVB Aug avg: -8.27% median: -10.10% win: 25% σ: 12.17% n: 4 2022-04-12 → 2026-07-31 (current) | ENVB Sep avg: -16.05% median: -15.48% win: 25% σ: 23.07% n: 4 2022-04-12 → 2026-07-31 | ENVB Oct avg: -16.52% median: -22.45% win: 25% σ: 14.92% n: 4 2022-04-12 → 2026-07-31 | ENVB Nov avg: -16.11% median: -15.63% win: 25% σ: 14.13% n: 4 2022-04-12 → 2026-07-31 | ENVB Dec avg: -16.97% median: -19.84% win: 25% σ: 19.82% n: 4 2022-04-12 → 2026-07-31 |